Novel therapies for treating acute agitation

Journal of Emergency Medicine

Volumn 27, Issue 4 SUPPL., 2004, Pages

  Currier, Glenn W ^a,b   Allen, Michael H ^c   Bunney, E Bradshaw ^d   Daniel, David G ^e   Francis, Andrew ^f   Jagoda, Andy ^g   Zimbroff, Dan ^h  

^a Department of Psychiatry ^*

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO HOSPITAL   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

^e Bioniche Development Inc   (United States)

^f STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h Pacific Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; LORAZEPAM; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

AGITATION; AKATHISIA; AMBLYOPIA; BIPOLAR DISORDER; CARDIOPULMONARY INSUFFICIENCY; CLINICAL TRIAL; DROWSINESS; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPEPSIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MOTOR DYSFUNCTION; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STEADY STATE; TREATMENT OUTCOME;

EID: 7044254649     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2004.09.002     Document Type: Article

References (25)

1. J. Battaglia, S.R. Lindborg, K. Alaka, K. Meehan, P. Wright Calming versus sedative effects of intramuscular olanzapine in agitated patients Am J Emerg Med 21 2003 192 198
2. Risperdal (package insert). Titusville, NJ: Janssen Pharmaceutica Products, L.P.; 2003.
3. Zyprexa, Zyprexa Zydis (package insert). Indianapolis, IN: Eli Lilly and Company; 2003.
4. M.H. Allen, D. Carpenter, J.L. Sheets, S. Miccio, R. Ross What do consumers say they want and need during a psychiatric emergency? J Psychiatr Pract 9 2003 39 58
5. H. Seager Drug-delivery products and the Zydis fast-dissolving dosage form J Pharm Pharmacol 50 1998 375 382
6. E.A. van Schaick, P. Lechat, B.M. Remmerie, G. Ko, K.C. Lasseter, E. Mannaert Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers Clin Ther 25 2003 1687 1699
7. G.W. Currier, J.C.Y. Chou, D Feifel Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam J Clin Psychiatry 65 2004 186 194
8. G.W. Currier, G.M. Simpson Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation J Clin Psychiatry 62 2001 153 157
9. R. Baker, B.J. Kinon, G.A. Maguire, H. Liu, A.L. Hill Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation J Clin Psychopharmacol 23 2003 342 348
10. Zyprexa (package insert). Indianapolis, IN: Eli Lilly and Company; 2004.
11. Eli Lilly and Company. Zyprexa powder for solution for injection. Summary of product characteristics. 2001. Available at: http://www.lilly.co.uk/pdf/ zyprexa%20intramuscular.pdf. Accessed September 1, 2003.
12. P. Wright, M. Birkett, S.R David Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia Am J Psychiatry 158 2001 1149 1151
13. A. Breier, K. Meehan, M Birkett A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia Arch Gen Psychiatry 59 2002 441 448
14. P. Wright, K. Meehan, M Birkett A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy Clin Ther 25 2003 1420 1428
15. K. Meehan, F. Zhang, S David A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania J Clin Psychopharmacol 21 2001 389 397
16. K.M. Meehan, H. Wang, S.R David Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia Neuropsychopharmacology 26 2002 494 504
17. Geodon (package insert). New York, NY: Pfizer Inc.; 2002.
18. D.G. Daniel, S.G. Potkin, K.R. Reeves, R.H. Swift, E.P. Harrigan Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial Psychopharmacology (Berl) 155 2001 128 134
19. M.D. Lesem, J.M. Zajecka, R.H. Swift, K.R. Reeves, E.P. Harrigan Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients J Clin Psychiatry 62 2001 12 18
20. S. Brook, J.V. Lucey, K.P. Gunn Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group J Clin Psychiatry 61 2000 933 941
21. R.H. Swift, E.P. Harrigan, J.C. Cappelleri, D. Kramer, L.P. Chandler Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients J Psychiatr Res 36 2002 87 95
22. Reeves KR, et al. Presented at: 38th Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting; June 10-13, 1998; Boca Raton, FL.
23. Data on file, Pfizer Inc., New York, NY.
24. Daniel DG, Brook S, Banattia I. Efficacy of IM ziprasidone without adjunctive benzodiazepines. Poster presented at: 156th Annual Meeting of the American Psychiatric Association, May 17-22, 2003; San Francisco, CA.
25. Klotz SG, Preval H, Southard R, Francis A. Injectable ziprasidone in the psychiatric emergency service. Poster presented at: 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.